BB Biotech AG with after-tax loss in the first quarter of 2016
(Thomson Reuters ONE) -
BB BIOTECH AG /
BB Biotech AG with after-tax loss in the first quarter of 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN
CH0038389992) is releasing the following information about its results for the
first quarter of 2016.
Based on preliminary unaudited consolidated results, BB Biotech AG closed the
first quarter of 2016 with a loss of CHF 1.2 billion (CHF 379 million profit in
the corresponding period of the previous year). As an investment company, the
results reflect the performance of the stocks it holds in its investment
portfolio.
The net income figure for the first quarter of 2016 reflects the overall
difficult start into 2016 for equity markets. The accelerated profit-taking in
the biotechnology sector was driven by many years of outperformance and the
continued debate over healthcare affordability and drug prices in the context of
the US presidential election campaigns. As a result, valuations in the sector
are particularly attractive and for large caps at a decade low.
BB Biotech's share price decreased 16.5% in CHF and 17.4% in EUR during the
corresponding period.
The interim report as of March 31, 2016 will be published on April 22, 2016.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Tanja
Chicherio, Tel. +41 44 267 67 07, tch(at)bellevue.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.
Press Release (PDF):
http://hugin.info/130285/R/2003255/739366.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via GlobeNewswire
[HUG#2003255]
Unternehmensinformation / Kurzprofil:
Datum: 13.04.2016 - 18:05 Uhr
Sprache: Deutsch
News-ID 463825
Anzahl Zeichen: 3045
contact information:
Town:
Schaffhausen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB Biotech AG with after-tax loss in the first quarter of 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
